Last Price
312.00
Today's Change
+1.13 (0.36%)
Day's Change
307.74 - 313.16
Trading Volume
108,161
Exchange: NASDAQ Global Select NASDAQ Global Select
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Mr. William J. Sibold Mr. William J. Sibold
Full Time Employees: 376 376
IPO Date: 2007-02-06 2007-02-06
CIK: 0001157601 0001157601
ISIN: US5588681057 US5588681057
CUSIP: 558868105 558868105
Beta: -0.47 -0.47
Last Dividend: 0.00 0.00
Dcf Diff: 311.79 311.79
Dcf: -0.92 -0.92
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.